{"id":751217,"date":"2023-04-26T06:33:30","date_gmt":"2023-04-26T10:33:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/"},"modified":"2023-04-26T06:33:30","modified_gmt":"2023-04-26T10:33:30","slug":"cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/","title":{"rendered":"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., April  26, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MKbJP70dozrekgqbkJcJY4fiXRWVABPHHtJETYNEPSXO3W5MuC8BpfYjKtUbg36KEDod0HgCXormYuEiXTbXIhDcwX7EYOLojiQ-auh-fQ4=\" rel=\"nofollow noopener\" target=\"_blank\">Cerevel Therapeutics<\/a>\u00a0(Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 2023 BofA Securities Health Care Conference.<\/p>\n<p>\n        <strong>Date:<\/strong> Wednesday, May 10th<\/p>\n<p>\n        <strong>Format:<\/strong> Presentation at 10:00 am PT (1:00 pm ET)<\/p>\n<p>The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uZglXUK1r8MA5egEGFbIoe5OiFR0fOql2re7jp8m7oAvyELAN-plzLVyBI_vPYHcwLYhe5j66OhyI_Z_Od5IDHuRZ-GSKSqcTWjiyWx6ZuU=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. A replay will be available in the same section of the company\u2019s website.<\/p>\n<p>\n        <strong>About Cerevel Therapeutics<\/strong><br \/>\n        <br \/>Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases by combining its deep expertise in neurocircuitry with a focus on targeted receptor subtype selectivity and a differentiated approach to pharmacology. Cerevel Therapeutics has a diversified pipeline comprised of five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, Alzheimer\u2019s disease psychosis, epilepsy, panic disorder, and Parkinson\u2019s disease. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R1OJcQKkSOpUGhP7qey93_5JdxKPwaASQEyaeEQ9KqyIUQ6BZY5PEiC63WPwqhamC8btgKFDiQkZH4gRVFm6zw==\" rel=\"nofollow noopener\" target=\"_blank\">www.cerevel.com<\/a><\/p>\n<p>\n        <strong>Special Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements that are based on management\u2019s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about: the potential attributes and benefits of our product candidates and our plan to present at an upcoming conference. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19, the post-COVID environment and other factors on the timing, progress and results of clinical trials; our ability to recruit and enroll suitable patients in our clinical trials; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed with the SEC on February 22, 2023 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.<\/em>\n      <\/p>\n<p>\n        <strong>Media Contacts:<\/strong><br \/>\n        <br \/>Anna Robinson <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ANVz6i-I8INJJbMRyIKtdoR6ir5l-pAbyMR_bPSjXVDl_ZmpHg18b6v3teT0eO6dRxgd7jbw3i-485If0pCRxZUuasNCrb3fns8br8UCPzs=\" rel=\"nofollow noopener\" target=\"_blank\">Anna.robinson@cerevel.com<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Matthew Calistri<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7evPQO3xohPg46XmUM5niOGO3dyBa1v58q30cN5U_HP2jwwH7POTnh84_cZfpe9RAgTU-kWtI1T1IW0cQAGrrr7ysoIhr3--qe60rg4u3FjW8urvaYL6mJmcpm36bk2R\" rel=\"nofollow noopener\" target=\"_blank\">Matthew.calistri@cerevel.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODMxZjFjNzktNjc1OS00NWZjLThkNGYtM2Y5YWY1YzUwYmQ3LTEyMDY5NjY=\/tiny\/Cerevel-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) &#8212; Cerevel Therapeutics\u00a0(Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 2023 BofA Securities Health Care Conference. Date: Wednesday, May 10th Format: Presentation at 10:00 am PT (1:00 pm ET) The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website\u00a0here. A replay will be available in the same section of the company\u2019s website. About Cerevel Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases by combining its deep expertise &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751217","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) &#8212; Cerevel Therapeutics\u00a0(Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 2023 BofA Securities Health Care Conference. Date: Wednesday, May 10th Format: Presentation at 10:00 am PT (1:00 pm ET) The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website\u00a0here. A replay will be available in the same section of the company\u2019s website. About Cerevel Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases by combining its deep expertise &hellip; Continue reading &quot;Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T10:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference\",\"datePublished\":\"2023-04-26T10:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/\"},\"wordCount\":740,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/\",\"name\":\"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM=\",\"datePublished\":\"2023-04-26T10:33:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) &#8212; Cerevel Therapeutics\u00a0(Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 2023 BofA Securities Health Care Conference. Date: Wednesday, May 10th Format: Presentation at 10:00 am PT (1:00 pm ET) The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website\u00a0here. A replay will be available in the same section of the company\u2019s website. About Cerevel Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases by combining its deep expertise &hellip; Continue reading \"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T10:33:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference","datePublished":"2023-04-26T10:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/"},"wordCount":740,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/","name":"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM=","datePublished":"2023-04-26T10:33:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTU2OCM1NTU3NDExIzIxOTU0MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cerevel-therapeutics-to-present-at-the-bofa-securities-2023-health-care-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751217"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751217\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}